O artykule
Article Category: In My View
Data publikacji: 21 kwi 2018
Zakres stron: 35 - 37
DOI: https://doi.org/10.17225/jhp.00023
© 2018
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Octapharma's core business is the development and production of human proteins from human plasma and cell lines. As the company moves into the recombinant arena, Chairman Wolfgang Marguerre discusses opportunities and threats with Editor-in-Chief Kate Khair